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In his influential book “The Structure of Scientific Revolutions” published in 1962, Thomas Kuhn 
argued that researchers in every field of scientific enquiry are always guided by theoretical assumptions, 
presuppositions, and hypotheses that constitute the prevailing scientific paradigm under which they 
operate at any given time (1). When they operate within a shared paradigm, a scientific community 
working in a particular field will be committed to using certain strategies and experimental approaches 
that are accepted as being essential for trying to solve the problem at hand.
In many cases, the implicit hypotheses and presuppositions that give rise to a particular paradigm 
are not clearly stated and investigators may therefore sometimes not even be aware of them. One 
consequence of this is that when they obtain results that are not compatible with the theory and 
hypotheses underlying the paradigm, they may fail to appreciate that their guiding paradigm has in 
fact been refuted and should therefore be abandoned or revised. On the other hand, according to Kuhn, 
scientists actually do not abandon their hypotheses and paradigms as soon as contradictory data are 
obtained, since their main goal is not to try to confirm the validity of the underlying assumptions of 
their paradigms. Scientific communities tend to remain committed to their shared theoretical beliefs 
even when they obtain anomalous results that are not consistent with the paradigm, and they will 
invent new ad hoc hypotheses in an attempt to resolve apparent contradictions between theory and 
experimental observations (2). Unfortunately, when misleading paradigms are not discarded, this may 
encourage scientists to pursue unfruitful lines of investigations that could impede scientific progress.
In the field of HIV vaccine research, there is in fact evidence that in recent years a number of 
paradigms based on invalid assumptions had such a detrimental effect (3). This drawback can only 
be avoided if scientists keep in mind that if the paradigms they have adopted are based on erroneous 
assumptions, this could lead them to select inappropriate research strategies that are unlikely to 
succeed. Questioning the validity of paradigms is thus an important safeguard since it may reveal 
which invalid assumptions have led investigators astray in the past. Only when past mistakes are 
acknowledged can novel paradigms be introduced, which better fit our improved knowledge of 
HIV-1 immune responses, and are therefore more likely to help future vaccine development (4, 5).
The following unwarranted assumptions underlying some popular paradigms in HIV vaccine research 
may have contributed to our inability during the past 25 years to develop an effective HIV-1 vaccine.
assumption No. 1: Vaccine immunogenicity can be Predicted 
from Viral antigenicity
Most fragments of a viral antigen are immunogenic and are able to induce antibodies that will react 
with the fragment. However, this type of immunogenicity is irrelevant for vaccination since these 
antibodies rarely recognize the cognate, intact antigen, and even more rarely neutralize the infectivity 
of the viral pathogen that harbors the antigen (6). A confusion between biological immunogenicity 
(the ability to induce antibodies in a host) and chemical antigenicity (the capacity of an antigen to bind 
antibodies) lies at the heart of the reverse vaccinology paradigm that has been pursued vigorously for 
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more than 10 years. According to this paradigm, HIV-1 epitopes 
identified by X-ray crystallographic analysis of complexes of HIV 
Env bound to affinity-matured neutralizing monoclonal antibodies 
(nMabs) were expected to be also effective vaccine immunogens 
able to induce a protective immune response. However, an epitope 
that binds to a nMab will not necessarily be able to induce the same 
type of neutralizing antibody in an immunized host. As discussed 
at length elsewhere (7), investigators who claim they are designing 
a vaccine immunogen are only improving the binding reactivity 
(i.e., the antigenicity) of a single epitope–paratope pair and are 
not actually designing a vaccine immunogen able to generate 
protective antibodies. Immunogenicity does depend on numerous 
factors that exist only in the context of the host immune system, 
and these are independent of the binding properties of the viral 
antigen used for immunization (8).
assumption No. 2: there is a Primary and 
intrinsic Epitope Specific for Each B Cell 
receptor and its Corresponding antibody
In reality, there is no single intrinsic epitope for any antibody 
molecule but only a diverse group of potential ligands able to 
bind to it with various degrees of fit (3). Vaccinologists have been 
slow to accept that antibodies are not monospecific for a single 
epitope and that the degeneracy of the immune system always 
makes antibodies polyspecific for numerous related or unrelated 
epitopes present in different antigens (9–11). Once it is accepted 
that the epitope identified by X-ray crystallography of an HIV-1 
Env-nMab complex is only one of the many epitopes that could 
be accommodated by that antibody, there is no justification for 
assuming that this particular HIV-1 epitope must correspond to 
the immunogen that elicited the nMab and should therefore be 
considered as a possible candidate vaccine.
assumption No. 3: HiV-1 Epitopes 
recognized by Mature nMabs isolated 
from HiV-1 infected individuals after a 
lengthy Process of antibody affinity 
Maturation will be able to induce a 
Protective immune response in  
Naive individuals
It has been established that the initial HIV-1 immunogen that trig-
gers the affinity maturation process leading to mature neutralizing 
antibodies usually recognizes a BCR germline version that differs 
considerably from the BCRs corresponding to mature antibodies 
(12). The very extensive affinity maturation required to obtain 
neutralizing HIV-1 antibodies is one of the main reasons why the 
structure-based reverse vaccinology approach did not succeed in 
developing an effective HIV-1 vaccine (3). A new paradigm based on 
the germline/maturation hypothesis was subsequently developed, 
which assumed that it may be possible to discover effective HIV-1 
vaccine immunogens by analyzing putative germline antibody 
intermediates of known HIV-1 nMabs (13). It is not clear at present 
whether the unraveling of large numbers of different antibody 
maturation pathways will allow the identification of HIV-1 vaccine 
immunogens suitable for vaccinating large human populations.
assumption No. 4: the so-called rational 
design of HiV-1 immunogens is More 
Effective than the Classical trial-and-
Error Screening of immunogens used in 
the Past for developing Successful 
Vaccines
Many authors claim that so-called “rational design” offers the best 
prospects for developing an HIV-1 vaccine. Design means the 
deliberate conceiving of a novel object or process by an intelligent 
being, while the term “rational” is mostly used to indicate that the 
designer makes use of available molecular data (8, 14). When they 
discuss the rational design of HIV-1 vaccines, these authors refer 
only to studies that try to improve the structural complementarity 
between one epitope and one particular Mab, which means they 
actually discuss antigen design and not immunogen design (15, 
16). Designing vaccine immunogenicity actually means modifying 
an antigen, so that it becomes an immunogen capable of inducing a 
protective immune response and this requires investigating empiri-
cally the numerous factors, which in an immunized host determine 
the formation of neutralizing antibodies. Unfortunately, we know 
very little about the immunological mechanisms in the host that 
produce neutralizing rather than non-neutralizing antibodies and 
our ignorance is what prevents us from deliberately “designing” 
vaccine immunogens of predetermined, known efficacy. Rationally 
designing an antigen so that it better fits a single Mab is certainly 
possible but improving an immunogen so that it is better able to 
elicit protective antibodies can only be achieved by trial-and-error 
experimentation with various immunogens and not by design (8, 
17). It is currently fashionable to denigrate empirical approaches 
in vaccine research (18), as if time-honored empiricism and trial-
and-error experimentation were not an entirely rational enterprise 
compatible with high quality science (3, 7, 14). Advocating rational 
design instead of stressing the need for more empirical research 
may even be counterproductive since it is likely to make it more 
difficult for investigators to undertake the small exploratory 
trial-and-error trials that are needed to move the field forward 
(5). Although epitope mapping with nMabs may indicate which 
regions of a virus surface should be targeted by a vaccine, such 
mapping on its own will not make it possible to discover effective 
vaccine immunogens if no immunogenicity trials are performed.
assumption No. 5: reactions of Viral 
antigens with Mabs are More Specific 
than the Combined reactivity of 
Polyclonal antibodies Found in an 
antiserum and are able to inform  
Vaccine design
The introduction of Mabs revolutionized our ability to dissect 
immune responses to proteins but it also introduced a bias in 
the analysis of antigens by encouraging investigators to focus on 
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artificial boundaries between overlapping epitopes and to concen-
trate on single, discrete epitopes as potential vaccine immunogens. 
The emphasis on single epitopes recognized by Mabs for developing 
vaccines tends to obscure the beneficial effect of the neutralizing 
synergy achievable with polyclonal responses (19).
The use of Mabs for characterizing epitopes also introduced 
another bias that occurs because the apparent specificity of a Mab 
very much depends on the selection process that was used to obtain 
it. When a nMab, for instance, binds to a short peptide region of 
the membrane proximate external region (MPER) of HIV-1 gp41, 
this may simply reflect the fact that the Mab was selected for its 
ability to bind to that peptide. Since all antibodies are polyspecific, 
the Mab may actually recognize better a more complex or transient 
epitope of gp41 that might have been the immunogen that elicited 
the antibody. However, if it is assumed that the Mab was induced by 
the linear MPER peptide region because it reacts with it, searching 
for an effective vaccine immunogen in gp41 may be compromised.
It is often believed that a Mab that binds to a given antigen is a 
more specific reagent than a polyclonal antiserum raised against 
that antigen. In reality, an antiserum has a greater collective 
specificity for a multiepitopic antigen due to the additive specificity 
effect that arises from the presence in the antiserum of antibodies 
directed to several different epitopes of the antigen (20).
It is sometimes suggested that the isolation of additional broadly 
neutralizing Mabs will facilitate the future rational design of an 
HIV-1 vaccine. Why this should be the case is not made clear since 
these Mabs only have the potential to perhaps 1 day become useful 
reagents for passive immunotherapy. However, their isolation does 
not improve our ability to discover which vaccine immunogens 
will elicit neutralizing antibodies by means of active immunization 
(14). Once again, confounding antigenicity and immunogenicity 
is giving rise to unrealistic expectations.
The aim of this Research Topic is to evaluate the shortcomings 
of some of the paradigms that guided HIV vaccine research in the 
past as well as to stimulate the search for novel paradigms that 
better fit our current understanding of immunological specificity 
and could be more helpful in guiding the future search for an 
effective HIV-1 vaccine.
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